Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UroGen Pharma (URGN) Current Deferred Revenue (2017)

UroGen Pharma's Current Deferred Revenue history spans 1 years, with the latest figure at $650000.0 for Q4 2017.

  • For Q4 2017, Current Deferred Revenue changed N/A year-over-year to $650000.0; the TTM value through Dec 2017 reached $650000.0, changed N/A, while the annual FY2017 figure was $650000.0, N/A changed from the prior year.
  • Current Deferred Revenue reached $650000.0 in Q4 2017 per URGN's latest filing.
  • In the past five years, Current Deferred Revenue ranged from a high of $650000.0 in Q4 2017 to a low of $650000.0 in Q4 2017.